Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications
Background/purpose: β-Tricalcium phosphate (β-TCP) is an osteoconductive material which has been used for clinical purposes for several years, as is polycaprolactone (PCL), which has already been approved for a number of medical and drug delivery devices. In this study we have incorporated various c...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-03-01
|
| Series: | Journal of Dental Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1991790216300538 |
| _version_ | 1819136818781618176 |
|---|---|
| author | Shu-Hsien Huang Tuan-Ti Hsu Tsui-Hsien Huang Cheng-Yao Lin Ming-You Shie |
| author_facet | Shu-Hsien Huang Tuan-Ti Hsu Tsui-Hsien Huang Cheng-Yao Lin Ming-You Shie |
| author_sort | Shu-Hsien Huang |
| collection | DOAJ |
| description | Background/purpose: β-Tricalcium phosphate (β-TCP) is an osteoconductive material which has been used for clinical purposes for several years, as is polycaprolactone (PCL), which has already been approved for a number of medical and drug delivery devices. In this study we have incorporated various concentrations of β-TCP into PCL with the aim of developing an injectable, mechanically strong, and biodegradable material which can be used for medical purposes without organic solvents.
Materials and methods: This study assesses the physical and chemical properties of this material, evaluates the in vitro bioactivity of the PCL/β-TCP composites, and analyzes cell proliferation and osteogenic differentiation when using human bone marrow mesenchymal stem cells (hBMSCs).
Results: The results show that weight losses of approximately 5.3%, 12.1%, 18.6%, and 25.2%, were observed for the TCP0, TCP10, TCP30, and TCP50 composites after immersion in simulated body fluid for 12 weeks, respectively, indicating significant differences (P < 0.05). In addition, PCL/β-TCP composites tend to have lower contact angles (47 ± 1.5° and 58 ± 1.7° for TCP50 and TCP30, respectively) than pure PCL (85 ± 1.3°), which are generally more hydrophilic. After 7 days, a significant (22% and 34%, respectively) increase (P < 0.05) in alkaline phosphatase level was measured for TCP30 and TCP50 in comparison with the pure PCL.
Conclusion: PCL/TCP is biocompatible with hBMSCs. It not only promotes proliferation of hBMSCs but also helps to differentiate reparative hard tissue. We suggest 50% (weight) PCL-containing β-TCP biocomposites as the best choice for hard tissue repair applications. |
| first_indexed | 2024-12-22T10:41:02Z |
| format | Article |
| id | doaj.art-80cace474617400c8990458640ad890f |
| institution | Directory Open Access Journal |
| issn | 1991-7902 |
| language | English |
| last_indexed | 2024-12-22T10:41:02Z |
| publishDate | 2017-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Dental Sciences |
| spelling | doaj.art-80cace474617400c8990458640ad890f2022-12-21T18:29:01ZengElsevierJournal of Dental Sciences1991-79022017-03-01121334310.1016/j.jds.2016.05.003Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applicationsShu-Hsien Huang0Tuan-Ti Hsu1Tsui-Hsien Huang2Cheng-Yao Lin3Ming-You Shie4School of Dentistry, Chung Shan Medical University, Taichung City, Taiwan3D Printing Medical Research Center, China Medical University Hospital, Taichung City, TaiwanSchool of Dentistry, Chung Shan Medical University, Taichung City, Taiwan3D Printing Medical Research Center, China Medical University Hospital, Taichung City, Taiwan3D Printing Medical Research Center, China Medical University Hospital, Taichung City, TaiwanBackground/purpose: β-Tricalcium phosphate (β-TCP) is an osteoconductive material which has been used for clinical purposes for several years, as is polycaprolactone (PCL), which has already been approved for a number of medical and drug delivery devices. In this study we have incorporated various concentrations of β-TCP into PCL with the aim of developing an injectable, mechanically strong, and biodegradable material which can be used for medical purposes without organic solvents. Materials and methods: This study assesses the physical and chemical properties of this material, evaluates the in vitro bioactivity of the PCL/β-TCP composites, and analyzes cell proliferation and osteogenic differentiation when using human bone marrow mesenchymal stem cells (hBMSCs). Results: The results show that weight losses of approximately 5.3%, 12.1%, 18.6%, and 25.2%, were observed for the TCP0, TCP10, TCP30, and TCP50 composites after immersion in simulated body fluid for 12 weeks, respectively, indicating significant differences (P < 0.05). In addition, PCL/β-TCP composites tend to have lower contact angles (47 ± 1.5° and 58 ± 1.7° for TCP50 and TCP30, respectively) than pure PCL (85 ± 1.3°), which are generally more hydrophilic. After 7 days, a significant (22% and 34%, respectively) increase (P < 0.05) in alkaline phosphatase level was measured for TCP30 and TCP50 in comparison with the pure PCL. Conclusion: PCL/TCP is biocompatible with hBMSCs. It not only promotes proliferation of hBMSCs but also helps to differentiate reparative hard tissue. We suggest 50% (weight) PCL-containing β-TCP biocomposites as the best choice for hard tissue repair applications.http://www.sciencedirect.com/science/article/pii/S1991790216300538β-tricalcium phosphatebiocompositesbiodegradableosteogenicpolycaprolactone |
| spellingShingle | Shu-Hsien Huang Tuan-Ti Hsu Tsui-Hsien Huang Cheng-Yao Lin Ming-You Shie Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications Journal of Dental Sciences β-tricalcium phosphate biocomposites biodegradable osteogenic polycaprolactone |
| title | Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications |
| title_full | Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications |
| title_fullStr | Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications |
| title_full_unstemmed | Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications |
| title_short | Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications |
| title_sort | fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications |
| topic | β-tricalcium phosphate biocomposites biodegradable osteogenic polycaprolactone |
| url | http://www.sciencedirect.com/science/article/pii/S1991790216300538 |
| work_keys_str_mv | AT shuhsienhuang fabricationandcharacterizationofpolycaprolactoneandtricalciumphosphatecompositesfortissueengineeringapplications AT tuantihsu fabricationandcharacterizationofpolycaprolactoneandtricalciumphosphatecompositesfortissueengineeringapplications AT tsuihsienhuang fabricationandcharacterizationofpolycaprolactoneandtricalciumphosphatecompositesfortissueengineeringapplications AT chengyaolin fabricationandcharacterizationofpolycaprolactoneandtricalciumphosphatecompositesfortissueengineeringapplications AT mingyoushie fabricationandcharacterizationofpolycaprolactoneandtricalciumphosphatecompositesfortissueengineeringapplications |